Last updated: March 10, 2026
Ampullary cancer arises from the ampulla of Vater where the bile duct and pancreatic duct meet the duodenum. It has better prognosis than pancreatic cancer due to earlier symptom presentation (jaundice). Can have intestinal or pancreatobiliary histology with different molecular profiles.
Active research areas in 2026:Standard of care: Pancreaticoduodenectomy (Whipple procedure) for resectable disease. Adjuvant chemotherapy (gemcitabine or capecitabine). For metastatic: treated similar to biliary tract cancer.
Before or instead of upfront surgery:
For unresectable or metastatic disease:
Checkpoint inhibitors for biomarker-selected patients:
KRAS mutations are common in ampullary cancer:
View all 12 ampullary cancer trials on ClinicalTrials.gov →
Trial listings from ClinicalTrials.gov. Page summaries generated by AI and may contain errors. Always verify with your healthcare provider.
Find Ampullary Cancer Trials Matched to Your Situation
Use ClinTrialFinder's AI-powered matching to find trials based on your specific histology and treatment history.
Find Matching Trials